University Of Iowa is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The University of Iowa (UIowa) is a major research university with a distinguished history in neuroscience and neurodegenerative disease research. Located in Iowa City, the university is home to the Iowa Neuroscience Institute and the Roy J. and Lucille A. Carver College of Medicine, which host world-class programs investigating Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative disorders.
| Attribute |
Details |
| Full Name |
University of Iowa |
| Location |
Iowa City, Iowa, USA |
| Type |
Public Research University (Ivy) |
| Founded |
1847 |
| Enrollment |
~30,000 students |
| Website |
uiowa.edu |
The University of Iowa was founded in 1847 as the first public university in the United States to admit men and women on equal terms. The Carver College of Medicine was established in 1870, and the university has been at the forefront of medical research ever since. The Iowa Neuroscience Institute was founded in 2015 under the leadership of Dr. Ted Abel, bringing together over 60 faculty members from various departments to study the nervous system and neurological diseases.
The university's Department of Neurology has a long-standing tradition of excellence in neurodegenerative disease research, dating back to the early studies on Huntington's disease in the 1970s. Today, UIowa is recognized as a Huntington's Disease Society of America Center of Excellence and participates in numerous clinical trials for AD, PD, and ALS.
Founded in 2015, the Iowa Neuroscience Institute brings together over 60 faculty members studying:
- Neurodegeneration mechanisms and protein aggregation
- Neural development and repair
- Psychiatric disorders neuroscience
- Computational neuroscience
The UIowa Center for Neurodegeneration focuses on:
- Alpha-synuclein aggregation and propagation in PD
- Mitochondrial dysfunction in Parkinson's disease
- RNA metabolism in ALS/FTD
- Neuroinflammation pathways
- Prion-like mechanisms of protein spread
UIowa has a long-standing HD research program, designated as a Huntington's Disease Society of America Center of Excellence:
- Genetic testing and counseling services
- Clinical trials participation
- Pathogenesis research
- Caregiver support programs
The Paulson Lab specializes in prion diseases and protein aggregation:
- Creutzfeldt-Jakob disease
- Fatal familial insomnia
- Gerstmann-Sträussler-Scheinker syndrome
- Novel therapeutic approaches
- Dr. Henry Paulson - Prion diseases, protein aggregation, FTD
- Dr. Peggy Taylor - Parkinson's disease, dopamine neuron biology
- Dr. Andrew Pieper - Neuroprotection, novel therapeutics, drug discovery
- Dr. Matthew Harper - ALS and FTD research, RNA binding proteins
- Dr. Kim K. Horton - Neuroinflammation and microglia biology
- Dr. Ted Abel - Neuroscience, memory, circadian rhythms (former director)
- Dr. Thaddeus Simon - Movement disorders, Parkinson's disease
- Alpha-synuclein strains: Discovery of distinct alpha-synuclein conformations with different pathogenic properties (Guo et al., Cell 2018)
- TDP-43 pathology: Found TDP-43 inclusions in ALS and FTD, now a hallmark pathology (Taylor et al., Nat Rev Neurol 2015)
- Novel neuroprotective compounds: Development of small molecules for neurodegenerative diseases (Pieper et al., Neuron 2019)
- Mitochondrial genetics: Identification of mitochondrial DNA variants affecting PD risk
- Huntington's disease biomarkers: Novel CSF and blood markers for disease progression
- Iowa Neuroscience Institute - State-of-the-art research building
- Carver College of Medicine - Medical research facilities
- University of Iowa Hospitals and Clinics - Clinical research
- In Vivo Imaging Facility - PET, MRI capabilities
- Genome Editing Facility - CRISPR-based research
- MD/PhD Program - Combined medical and research training
- PhD in Neuroscience - Interdisciplinary graduate program
- Neurology Residency - ACGME-accredited training
- Postdoctoral Fellowships - NIH-funded positions
- Michael J. Fox Foundation - Parkinson's disease research
- Alzheimer's Association - AD clinical trials
- CHDI Foundation - Huntington's disease research
- ALS Association - ALS therapy development
| Disease |
Research Intensity |
| Parkinson's Disease |
High |
| Alzheimer's Disease |
High |
| Huntington's Disease |
High |
| ALS |
Moderate-High |
| Frontotemporal Dementia |
Moderate |
| Prion Diseases |
Moderate |
The study of University Of Iowa has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Taylor JP, et al. (2015). Decoding ALS: from genes to mechanism. Nature Reviews Neurology.
- Guo JL, et al. (2018). Distinct α-Synuclein strains. Cell.
- Pieper AA, et al. (2019). Neuroprotective compounds for neurodegenerative diseases. Neuron.
- Cook C, et al. (2020). TDP-43 pathology in neurodegeneration. Acta Neuropathologica.
- Paulson HL, et al. (2017). Prion diseases. Continuum (Minneap Minn).
- Harper SM, et al. (2021). RNA binding proteins in ALS/FTD. Nature Reviews Neurology.
- University of Iowa Neurology Annual Research Reports 2020-2024.